PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.43%
Cash & equivalents declining -3.43% while AVXL's grows 6.85%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-3.43%
Below half of AVXL's 6.85%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
967.92%
Above 1.5x AVXL's 49.74%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-3.05%
Below half of AVXL's 7.29%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
0.98%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to AVXL's zero value, indicating worse performance.
0.98%
Higher Total Non-Current Assets Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Below half of AVXL's 7.29%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-106.99%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
16.37%
Above 1.5x AVXL's 5.84%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of AVXL's 96776.48%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
2.58%
Less than half of AVXL's 5.84%. David Dodd sees far fewer liability expansions relative to competitor.
3.85%
1.25-1.5x AVXL's 2.82%. Martin Whitman sees potential dilution risk vs. competitor approach.
-5.06%
Similar yoy to AVXL's -5.07%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.22%
Below half AVXL's 7.43%. Michael Burry sees potential underperformance in building shareholder capital.
-2.92%
Below half AVXL's 7.29%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-5.00%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
3.39%
Less than half of AVXL's -6.85%. David Dodd sees better deleveraging or stronger cash buildup than competitor.